Alto Neuroscience identifies EEG biomarker and positive Phase 2 results for ALTO-203 in MDD

Alto Neuroscience, Inc.

ALTO-203 showed pro-cognitive and wake-promoting effects; EEG theta/beta ratio confirmed as key biomarker (25µg: p<0.05).
Improvements in sustained attention replicated Phase 1 findings; greatest in patients with high baseline theta/beta ratio (25µg: p<0.01; 75µg: p<0.05).
Objective sleep measures from wearables confirmed wake-promotion; both doses significant (25µg: p<0.05; 75µg: p<0.001 vs placebo).
MADRS improvements were small (25µg: -2 points at week 3 vs placebo) but trial not powered for significance.
Safety profile: well tolerated, insomnia most common adverse event; predictable PK.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.